Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 2,500 | 0 | 0 | 0 | 3,551 |
| Gross Profit | 2,500 | N/A | N/A | N/A | 3,551 |
| Operating Expenses | 163,912 | 162,203 | 176,141 | 126,191 | 140,096 |
| Operating Income | -161,412 | -162,203 | -176,141 | -126,191 | -136,545 |
| Interest Expense | 21,646 | 14,647 | 5,094 | 7,244 | 5,367 |
| Other Income | 7,943 | 4,052 | 7,258 | 6,439 | 3,223 |
| Pre-tax Income | -175,115 | -172,798 | -173,977 | -126,996 | -138,689 |
| Income Tax | 103 | 546 | N/A | N/A | -3,313 |
| Net Income Continuous | -175,218 | -173,344 | -173,977 | -126,996 | -135,376 |
| Minority Interests | -2,133 | -2,808 | -3,184 | -1,696 | -2,512 |
| Net Income | $-173,085 | $-170,536 | $-170,793 | $-125,300 | $-132,864 |
| EPS Basic Total Ops | -1.39 | -1.36 | -1.38 | -1.02 | -1.24 |
| EPS Basic Continuous Ops | -1.40 | -1.40 | -1.40 | -1.03 | -1.26 |
| EPS Diluted Total Ops | -1.39 | -1.36 | -1.38 | -1.02 | -1.24 |
| EPS Diluted Continuous Ops | -1.40 | -1.40 | -1.40 | -1.03 | -1.26 |
| EPS Diluted Before Non-Recurring Items | -1.39 | -1.38 | -1.38 | N/A | N/A |
| EBITDA(a) | $-156,177 | $-168,308 | $-164,369 | $-119,935 | $-133,117 |